Literature DB >> 28205574

Neuropathic pain.

Luana Colloca1, Taylor Ludman1, Didier Bouhassira2, Ralf Baron3, Anthony H Dickenson4, David Yarnitsky5, Roy Freeman6, Andrea Truini7, Nadine Attal8, Nanna B Finnerup9, Christopher Eccleston10,11, Eija Kalso12, David L Bennett13, Robert H Dworkin14, Srinivasa N Raja15.   

Abstract

Neuropathic pain is caused by a lesion or disease of the somatosensory system, including peripheral fibres (Aβ, Aδ and C fibres) and central neurons, and affects 7-10% of the general population. Multiple causes of neuropathic pain have been described and its incidence is likely to increase owing to the ageing global population, increased incidence of diabetes mellitus and improved survival from cancer after chemotherapy. Indeed, imbalances between excitatory and inhibitory somatosensory signalling, alterations in ion channels and variability in the way that pain messages are modulated in the central nervous system all have been implicated in neuropathic pain. The burden of chronic neuropathic pain seems to be related to the complexity of neuropathic symptoms, poor outcomes and difficult treatment decisions. Importantly, quality of life is impaired in patients with neuropathic pain owing to increased drug prescriptions and visits to health care providers, as well as the morbidity from the pain itself and the inciting disease. Despite challenges, progress in the understanding of the pathophysiology of neuropathic pain is spurring the development of new diagnostic procedures and personalized interventions, which emphasize the need for a multidisciplinary approach to the management of neuropathic pain.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28205574      PMCID: PMC5371025          DOI: 10.1038/nrdp.2017.2

Source DB:  PubMed          Journal:  Nat Rev Dis Primers        ISSN: 2056-676X            Impact factor:   52.329


  202 in total

1.  Development and testing of a neuropathic pain screening questionnaire: ID Pain.

Authors:  Russell Portenoy
Journal:  Curr Med Res Opin       Date:  2006-08       Impact factor: 2.580

Review 2.  Psychological therapies for the management of chronic neuropathic pain in adults.

Authors:  Christopher Eccleston; Leslie Hearn; Amanda C de C Williams
Journal:  Cochrane Database Syst Rev       Date:  2015-10-29

3.  Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4).

Authors:  Didier Bouhassira; Nadine Attal; Haiel Alchaar; François Boureau; Bruno Brochet; Jean Bruxelle; Gérard Cunin; Jacques Fermanian; Patrick Ginies; Aurélie Grun-Overdyking; Hélène Jafari-Schluep; Michel Lantéri-Minet; Bernard Laurent; Gérard Mick; Alain Serrie; Dominique Valade; Eric Vicaut
Journal:  Pain       Date:  2005-01-26       Impact factor: 6.961

4.  Dynamic Pain Phenotypes are Associated with Spinal Cord Stimulation-Induced Reduction in Pain: A Repeated Measures Observational Pilot Study.

Authors:  Claudia M Campbell; Luis F Buenaver; Srinivasa N Raja; Kasey B Kiley; Lauren J Swedberg; Paul W Wacnik; Steven P Cohen; Michael A Erdek; Kayode A Williams; Paul J Christo
Journal:  Pain Med       Date:  2015-03-20       Impact factor: 3.750

5.  A randomized controlled pilot study of a cognitive-behavioral therapy approach for painful diabetic peripheral neuropathy.

Authors:  John D Otis; Kristen Sanderson; Christina Hardway; Michael Pincus; Carlos Tun; Sharona Soumekh
Journal:  J Pain       Date:  2013-02-26       Impact factor: 5.820

Review 6.  Epidural steroids: a comprehensive, evidence-based review.

Authors:  Steven P Cohen; Mark C Bicket; David Jamison; Indy Wilkinson; James P Rathmell
Journal:  Reg Anesth Pain Med       Date:  2013 May-Jun       Impact factor: 6.288

7.  Effect of variability in the 7-day baseline pain diary on the assay sensitivity of neuropathic pain randomized clinical trials: an ACTTION study.

Authors:  John T Farrar; Andrea B Troxel; Kevin Haynes; Ian Gilron; Robert D Kerns; Nathaniel P Katz; Bob A Rappaport; Michael C Rowbotham; Ann M Tierney; Dennis C Turk; Robert H Dworkin
Journal:  Pain       Date:  2014-05-14       Impact factor: 6.961

8.  Chronic pain with neuropathic characteristics in diabetic patients: a French cross-sectional study.

Authors:  Didier Bouhassira; Martine Letanoux; Agnès Hartemann
Journal:  PLoS One       Date:  2013-09-13       Impact factor: 3.240

9.  Estimating the burden of disease in chronic pain with and without neuropathic characteristics: does the choice between the EQ-5D and SF-6D matter?

Authors:  Nicola Torrance; Kenny D Lawson; Ebenezer Afolabi; Michael I Bennett; Michael G Serpell; Kate M Dunn; Blair H Smith
Journal:  Pain       Date:  2014-07-11       Impact factor: 6.961

10.  Mexiletine as a treatment for primary erythromelalgia: normalization of biophysical properties of mutant L858F NaV 1.7 sodium channels.

Authors:  R Cregg; J J Cox; D L H Bennett; J N Wood; R Werdehausen
Journal:  Br J Pharmacol       Date:  2014-08-29       Impact factor: 8.739

View more
  419 in total

1.  TRESK Regulates Gm11874 to Induce Apoptosis of Spinal Cord Neurons via ATP5i Mediated Oxidative Stress and DNA Damage.

Authors:  Pei Liu; Ye Cheng; Huiling Xu; Haicheng Huang; Simin Tang; Fuhu Song; Jun Zhou
Journal:  Neurochem Res       Date:  2021-05-10       Impact factor: 3.996

Review 2.  Motor Cortex Stimulation for Deafferentation Pain.

Authors:  Ahmed E Hussein; Darian R Esfahani; Galina I Moisak; Jamil A Rzaev; Konstantin V Slavin
Journal:  Curr Pain Headache Rep       Date:  2018-05-23

3.  Anti-nociceptive Role of CXCL1 in a Murine Model of Peripheral Nerve Injury-induced Neuropathic Pain.

Authors:  Ling Cao; Jennifer T Malon
Journal:  Neuroscience       Date:  2018-01-06       Impact factor: 3.590

4.  Getting a handle on CaV2.2 (N-type) voltage-gated Ca2+ channels.

Authors:  Jörg Striessnig
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-11       Impact factor: 11.205

5.  MiR-122-5p suppresses neuropathic pain development by targeting PDK4.

Authors:  Lanlan Wan; Zhen Su; Fayin Li; Pengfei Gao; Xianlong Zhang
Journal:  Neurochem Res       Date:  2021-02-10       Impact factor: 3.996

6.  Chronic nanocurcumin treatment ameliorates pain-related behavior, improves spatial memory, and reduces hippocampal levels of IL-1β and TNFα in the chronic constriction injury model of neuropathic pain.

Authors:  Sepideh Saffarpour; Atousa Janzadeh; Behnaz Rahimi; Fatemeh Ramezani; Farinaz Nasirinezhad
Journal:  Psychopharmacology (Berl)       Date:  2021-01-06       Impact factor: 4.530

7.  Efficacy and tolerability of nortriptyline in the management of neuropathic corneal pain.

Authors:  M Cuneyt Ozmen; Gabriela Dieckmann; Stephanie M Cox; Ramy Rashad; Rumzah Paracha; Nedda Sanayei; Melina I Morkin; Pedram Hamrah
Journal:  Ocul Surf       Date:  2020-08-27       Impact factor: 5.033

8.  Preface: Part II: The Fascinating Mechanisms and Implications of the Placebo Effect.

Authors:  Luana Colloca
Journal:  Int Rev Neurobiol       Date:  2018       Impact factor: 3.230

Review 9.  Pain Modulation: From Conditioned Pain Modulation to Placebo and Nocebo Effects in Experimental and Clinical Pain.

Authors:  Janie Damien; Luana Colloca; Carmen-Édith Bellei-Rodriguez; Serge Marchand
Journal:  Int Rev Neurobiol       Date:  2018-08-14       Impact factor: 3.230

Review 10.  Long noncoding RNA (lncRNA): a target in neuropathic pain.

Authors:  Shaogen Wu; Jamie Bono; Yuan-Xiang Tao
Journal:  Expert Opin Ther Targets       Date:  2018-12-02       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.